Descripción del proyecto
Terapia combinatoria para el tratamiento de enfermedades inflamatorias mediadas por inmunidad
Las enfermedades inflamatorias mediadas por inmunidad (EIMI) son un grupo de enfermedades autoinmunitarias heterogéneas con algunas características comunes a nivel molecular y celular; entre ellas figuran la artritis reumatoide, la psoriasis, la enfermedad de Crohn, la colitis ulcerosa y el lupus eritematoso sistémico. El objetivo del proyecto financiado con fondos europeos DocTIS es mejorar sustancialmente el pronóstico de las EIMI al identificar terapias combinatorias eficaces, así como los grupos de pacientes que muestran una respuesta óptima al tratamiento. Gracias al empleo de muestras de biobancos especializados en EIMI, se obtendrán nuevos datos moleculares mediante tecnologías avanzadas de alto rendimiento. Se emplearán métodos de biología de sistemas para modelar las respuestas a terapias dirigidas y predecir qué combinaciones de fármacos actuarán de forma sinérgica. Para proporcionar una prueba de concepto, después de la etapa preclínica, se probará la terapia combinatoria óptima en un grupo de pacientes con un perfil de biomarcadores positivo.
Objetivo
Immune-Mediated Inflammatory Diseases (IMIDs) are a group of common autoimmune diseases that include clinically heterogeneous disorders such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and systemic lupus erythematosus. Despite their clinical heterogeneity, IMIDs share a significant number of features at the molecular and cellular levels. Recently developed therapies targeting common key molecules of the immune system like anti-TNF agents, have collectively resulted in a significant improvement in the management of IMIDs. Still, the complete control of the chronic inflammatory process is rarely attained, and too many patients experience a poor response, if at all. This inefficacy has become a major economic burden and severely impacts on the wellbeing of many European citizens. The DocTIS projects aims to profoundly change this trend by identifying highly effective combinatorial therapies as well as the group of patients where this response will be optimal. Using the standardized samples from one of the world’s largest biobanks specialized in IMIDs, new molecular data will be generated using advanced high-throughput technologies including single cell RNA-seq. Systems biology methods will be applied to this unique clinical and molecular data to model the response to targeted therapies and predict what drug combinations will act synergistically and on which types of patients. After validation in a preclinical stage, the optimal combinatorial therapy will be tested in a group of patients with a positive biomarker profile. Using a basket trial, a new type of clinical trial design that incorporates molecular marker information, the DocTIS project will provide proof of concept of the utility of combinatorial therapy and personalized medicine for the effective control of disease activity in IMIDs.
Ámbito científico
- medical and health sciencesclinical medicinerheumatology
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesclinical medicinegastroenterologyinflammatory bowel disease
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health scienceshealth sciencespersonalized medicine
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2019-Two-Stage-RTD
Régimen de financiación
RIA - Research and Innovation actionCoordinador
08035 Barcelona
España